Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $128.35 | Total: $641.75 |
| 1 | 10 | $108.72 | Total: $1,087.20 |
| 1 | 25 | $92.11 | Total: $2,302.75 |
| 1 | 50 | $78.52 | Total: $3,926.00 |
| 1 | 100 | $67.95 | Total: $6,795.00 |
Overview
Milademetan (DS-3032) is an orally active and potent MDM2 inhibitor with antitumor activity that induces G1 cell cycle arrest, senescence, and apoptosis.Milademetan is used in the study of acute myeloid leukemia and solid tumors.
Chemical Properties
| Molecular Formula | C30H34Cl2FN5O4 |
| Molecular Weight | 618.53 |
| CAS Numbers | 1398568-47-2 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC1(C)CCC2(CC1)N[C@H]([C@H](c1ccnc(Cl)c1F)[C@]21C(=O)Nc2cc(Cl)ccc12)C(=O)N[C@@H]1CC[C@H](OC1)C(N)=O |
Storage and Handling
0C Short Term, -20C Long Term
References
M.M. Gounder,et al. Milademetan, an oral MDM2 inhibitor, in well-differentiateddedifferentiated liposarcoma results from a phase 1 study in patients with solid tumors or lymphomas. European Journal of Cancer 138S2 [2020] S1